December 16, 2021Open Access

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Key Points

Key points are not available for this paper at this time.

Abstract

In this 5-year update of ECHELON-2, frontline treatment of patients with PTCL with A+CHP continues to provide clinically meaningful improvement in PFS and OS versus CHOP, with a manageable safety profile, including continued resolution or improvement of peripheral neuropathy.

AI에게 질문

Bookmark

View Full Paper

Cite This Study

Horwitz et al. (Thu,) studied this question.

synapsesocial.com/papers/69d97e215e5bcb4e3b836d50 https://doi.org/https://doi.org/10.1016/j.annonc.2021.12.002

AI에게 질문

Bookmark

View Full Paper